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Dysregulation of the haem‑haemopexin
axis is associated with severe malaria
in a case–control study of Ugandan children
Robyn E. Elphinstone1,2,3, Frank Riley4, Tian Lin4, Sarah Higgins1,2,3, Aggrey Dhabangi5, Charles Musoke5,
Christine Cserti‑Gazdewich6, Raymond F. Regan7, H. Shaw Warren4† and Kevin C. Kain1,2,3*†

Abstract
Background: Malaria is associated with haemolysis and the release of plasma haem. Plasma haem can cause
endothelial injury and organ dysfunction, and is normally scavenged by haemopexin to limit toxicity. It was hypoth‑
esized that dysregulation of the haem-haemopexin pathway contributes to severe and fatal malaria infections.
Methods: Plasma levels of haemin (oxidized haem), haemopexin, haptoglobin, and haemoglobin were quantified in
a case–control study of Ugandan children with Plasmodium falciparum malaria. Levels at presentation were compared
in children with uncomplicated malaria (UM; n = 29), severe malarial anaemia (SMA; n = 27) or cerebral malaria (CM;
n = 31), and evaluated for utility in predicting fatal (n = 19) vs non-fatal (n = 39) outcomes in severe disease. A causal
role for haemopexin was assessed in a pre-clinical model of experimental cerebral malaria (ECM), following disruption
of mouse haemopexin gene (hpx). Analysis was done using Kruskall Wallis tests, Mann–Whitney tests, log-rank tests for
survival, and repeated measures ANOVA.
Results: In Ugandan children presenting with P. falciparum malaria, haemin levels were higher and haemopexin
levels were lower in SMA and CM compared to children with UM (haemin, p < 0.01; haemopexin, p < 0.0001). Among
all cases of severe malaria, elevated levels of haemin and cell-free haemoglobin at presentation were associated
with subsequent mortality (p < 0.05). Compared to ECM-resistant BALB/c mice, susceptible C57BL/6 mice had lower
circulating levels of haemopexin (p < 0.01), and targeted deletion of the haemopexin gene, hpx, resulted in increased
mortality compared to their wild type littermates (p < 0.05).
Conclusions: These data indicate that plasma levels of haemin and haemopexin measured at presentation correlate
with malaria severity and levels of haemin and cell-free haemoglobin predict outcome in paediatric severe malaria.
Mechanistic studies in the ECM model support a causal role for the haem-haemopexin axis in ECM pathobiology.
Keywords: Severe malaria, Cerebral malaria, Severe malarial anaemia, Haemopexin, Haptoglobin, Haem,
Haemoglobin, Experimental cerebral malaria
Background
Severe malaria (SM), including severe malarial anaemia
(SMA) and cerebral malaria (CM), is associated with
high fatality rates [1, 2]. Although the pathogenesis of SM
remains unclear, fatal disease is associated with increased
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†
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parasite burdens, excessive inflammation, endothelial
activation, and multi-organ dysfunction [1–3]. During
malaria infection there is haemolysis of both parasitized
and non-parasitized erythrocytes causing the release of
cell-free haemoglobin. Cell-free haemoglobin is readily oxidized to methaemoglobin which releases plasma
haem. Plasma haem is toxic to vascular endothelium via
a number of established mechanisms, including ironmediated oxidative stress, increased complement activation [4], induction of pro-inflammatory mediators [5],
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exocytosis of Weibel-Palade bodies [4, 6], increased leukocyte and platelet adhesion [6], and cell death [7]. Under
normal physiological states, cell-free haemoglobin and
haem are promptly bound by circulating haptoglobin
and haemopexin, respectively, leading to their inactivation via various pathways, including by haem-oxygenase
1 [8]. However, in conditions of intravascular haemolysis
these protective pathways may be overwhelmed resulting
in oxidative stress, reduced nitric oxide bioavailability,
inflammation, endothelial activation, and platelet/fibrin
microthrombi that together culminate in vascular dysfunction and multi-organ injury.
Malaria causes haemolysis, however the key components of the haem axis, specifically haemopexin and its
role, have not been well studied in SM. This study tests
the hypothesis that severe malarial syndromes are associated with higher plasma haem and lower levels of haemopexin and haptoglobin. Using a case–control study the
association of the haem axis with severe and fatal malaria
in African children was investigated. These investigations
were extended to explore a potential mechanistic role for
haemopexin using a pre-clinical animal model.

Methods
Study participants

This case–control study was nested within a large,
observational, prospective study of febrile children
(0.5–10.6 years) presenting with smear-confirmed Plasmodium falciparum malaria to Mulago Hospital [9].
Mulago Hospital is the district hospital for Kampala,
which is located in central Uganda, a region with moderate or meso-endemicity. All study participants were
local residents. Children were eligible for enrolment in
this study if they met WHO criteria for SMA (Hb <5.0 g/
dL) or CM [BCS <3, either before or >6 h after seizures
(or anticonvulsant medication), OR >3 seizures witnessed
within a 24-hour period; and, absence of hypoglycemia
(<2.2 mM), lumbar puncture evidence of bacterial meningitis or intracranial haemorrhage or any known nonmalaria-related neurologic abnormalities which may
alternatively explain coma] [10], or had uncomplicated
malaria (UM) (Hb >7.0 g/dL, platelet count >100,000/
uL, with absence of hypoxia, lactic acidosis, respiratory
distress, seizures, and coma); and, had a pre-treatment
plasma sample collected at presentation and stored frozen (without a freeze–thaw) until analysis. No children
had a history of haemoglobinopathy. All of the children
in this study were tested for haemoglobin S (HbS) using
SickleDex® (Streck Laboratories, Omaha, NB, USA)
(except n = 6). Children were excluded from the larger
trial if they had severe malnutrition that necessitated
transfer to the Nutrition Ward (based on clinical judgement of the attending physician); or if they had a history
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of HIV/AIDS or a positive HIV ELISA test [9]. Children
are routinely screened for HIV as part of their clinical
care. Children were tested for HIV using a screening
assay, and any positive tests were confirmed with a second ELISA. All children were treated according to Ugandan national malaria guidelines for the treatment of SM
and standard operating procedures at Mulago Hospital
[9]. This study was approved by the Mulago Hospital
Research Ethics Committee, Makerere University, Faculty of Medicine Research Ethics Committee, Uganda
National Council for Science & Technology, and the University Health Network. Written informed consent was
provided by a parent/guardian prior to enrolment.
Plasma haem is readily oxidized to haemin, therefore, plasma haemin was measured using a colorimetric
assay (BioVision, Milpitas, CA, USA). ELISA was used to
measure concentrations of cell-free haemoglobin (Bethyl
Laboratories, Montgomery, TX, USA), haemopexin and
haptoglobin (GenWay Biotech, San Diego, CA, USA).
The limits of detection were: haemin 0.5–600 µM;
cell-free haemoglobin 22–16,000 µg/mL; haemopexin
63–4000 µg/mL, and haptoglobin 2–2000 µg/mL. A
standard curve was run for each assay with manufacturer’s standards, as well as normal human serum to confirm
no assay-to-assay variation.
Experimental cerebral malaria (ECM)
Determining endogenous levels of haemopexin
in ECM‑resistant and ‑susceptible mice

Wild type C57BL/6 mice (highly susceptible to ECM)
and wild type BALB/c mice (moderately resistant to
ECM) were purchased from Jackson Laboratories (Sacramento, CA, USA). Female mice were used between
eight and 12 weeks of age. Plasmodium berghei ANKA
was obtained from MR4 (MRA-311) and cryopreserved
stocks were passaged through mice prior to infection. Mice were infected intraperitoneally with 106 P.
berghei ANKA-infected erythrocytes. On the day of
tissue collection (either day 6 or day 7 post infection,
dependent on infection kinetics), heparinized plasma was
collected via cardiac puncture.
Determining the susceptibility of haemopexin‑deficient mice

Haemopexin heterozygous mice were kindly provided by Dr Frank Berger (University of South Carolina), and were originally derived from Tolosano et al.
[11]. These mice are on a mixed C57BL/6; 129S6/Sv
background and heterozygous mice were bred. In all
experiments, littermates, both males and females ages
8–12 weeks, were used. Mice were infected with 105
P. berghei ANKA-infected erythrocytes injected intraperitoneally. The mice were followed daily for peripheral parasitaemia determined by thin blood smear.
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Infected mice followed for survival were euthanized
when moribund, which included signs of ECM, including limb paralysis, seizures and coma, or a greater than
20 % decrease in body weight. Plasma was collected
from infected mice via saphenous vein bleeds or when
moribund via cardiac puncture. Animal studies were
reviewed and approved by the University Health Network Animal Care Committee. Murine plasma was
stored frozen at −80 °C until analysis. ELISAs were
used to measure plasma levels of murine haptoglobin
and murine haemopexin (Immunology Consultants
Laboratory, Portland, OR, USA), and haemin was
measured using a colorimetic assay (BioVision, Milpitas, CA, USA). The limits of detection for the murine
markers were: haemopexin 125–16,000 ug/mL, haptoglobin 39–5000 ug/mL and haemin 0.2–8.4 uM.
Statistical analysis

Survival was analysed using the log-rank test; repeated
measures ANOVA was used to compare levels of murine
haemopexin or haptoglobin over time between genotypes; non-parametric analyses was used to compare
plasma levels, either Mann–Whitney tests or Kruskal–
Wallis analysis followed by Dunn’s Multiple Comparison
tests. All statistical analyses were performed using Graph
Pad Prism 6 or IBM SPSS Statistics Version 22.

Results
Children with severe malaria

This study included cases of SM, either CM (n = 31) or
SMA (n = 27), and children with UM (n = 29) as controls. Of the children with SM, there were 19 deaths and

39 survivors. None of the children had sickle cell disease (HbSS), and six of the children had sickle cell trait
(HbAS) (UM, n = 2; SMA, n = 2; CM, n = 2; including
one death). Patient characteristics are shown in Table 1.
At presentation children with SMA had 11-fold [median
(IQR): 11.1 µM (2.4, 26.9), p < 0.01] and CM had 15-fold
higher [15.8 (5.2, 30.6), p < 0.001] median plasma levels
of haemin compared to children with UM [1.0 (0.5, 6.5);
Fig. 1]. Children with UM had significantly higher levels
of haemopexin [993 µg/mL (766, 1144)] than those with
SMA [221 (63, 338); p < 0.0001] or CM [292 (106, 525);
p < 0.0001; Fig. 1]. Similarly, haptoglobin levels were
significantly higher in patients with UM [109 µg/mL (6,
1130)] compared to those with SMA (2 [2, 6]; p < 0.0001)
or CM (7 [3, 17]; p < 0.05). Haptoglobin levels were significantly lower in children with SMA compared to CM
(p < 0.05; Fig. 1).
Since both children with CM or SMA showed similar
evidence of dysregulation of the haem axis, the association of haemin and cell-free haemoglobin levels with outcome was then examined. Among children with SM (CM
and SMA cases combined) plasma levels of both haemin
[23.0 µM (6, 47.9) vs 8.4 (2.3, 20.30), p = 0.03] and cellfree haemoglobin [734.0 µg/mL (196.0, 2255) vs 222.0
(84.0, 669), p = 0.01] were significantly higher at presentation in those who subsequently went on to die of their
infection compared to children who survived (Fig. 2).
Sub-group analysis of children with either CM or SMA
showed similar trends with respect to levels of haemin
and cell-free haemoglobin and an increased risk of fatal
outcome but these did not reach statistical significance
(Additional file 1: Figure S1).

Table 1 Descriptive characteristics of the patient population
Combined SM (All children with SMA or CM)
Characteristic

UM (n = 29)

CM (n = 31)

SMA (n = 27)

P value

Survivors (n = 39)

Deaths (n = 19)

P value
0.301

Gender (% female)

48.3

58.1

48.1

0.679

48.7

63.2

Age (years)

3.2 (2.1, 7.4)***

3.1 (1.5, 4.4)##

1.3 (1.0, 2.2)##,***

0.000

1.9 (1.0, 4.0)

2.1 (1.3, 3.4)

0.673

Days reported ill prior
to presentation

3 (2, 4)*

3 (2, 4)##

4 (3, 5)*,##

0.004

3 (3, 4)

3 (2, 5)

0.496

Parasitaemia
(parasites/uL)

6.0 × 104 (9.9 ×103,
1.4 × 105)

8.2 × 104 (1.8 × 104,
2.8 × 105)

3.2 × 104 (5.3 × 103,
1.4 × 105)

0.090
0.000

1.6 × 105 (1.8 × 104,
4.4 × 105)

0.106

3.8 (3.2, 4.6)###,***

3.7 × 104 (6.2 × 103,
1.4 × 105)

162 (104, 258)$$$

67 (43, 128)$$$

126 (86, 180)

13 (10, 15)##

10 (7.5, 11)##,***

13

6

Red blood cell
haemoglobin (g/dL)
Platelet count (x109/L)

10.0 (9.2, 11.3)***,$$

Weight (kg)

14 (11, 22)

Fatal cases (count)

0

***

7.1 (5.8, 9.3)###,$$

4.7 (3.5, 7.1)

5.4 (4.6, 8.3)

0.134

0.001

95 (50, 174)

73 (41, 128)

0.230

0.000

10 (8, 14)

11 (10, 13)

0.269

0

19

Continuous variables analysed by Mann–Whitney, or Kruskall Wallis with Dunn’s multiple comparisons; categorical variable analysed by Chi square analysis
Median (IQR), uncomplicated malaria (UM), cerebral malaria (CM), severe malarial anaemia (SMA), severe malaria (SM)
Dunn’s multiple comparison tests: UM vs SMA * p < 0.05, *** p < 0.001; UM vs CM $$ p < 0.01, $$$ p < 0.001; CM vs SMA # p < 0.05, ## p < 0.01, ### p < 0.001
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Fig. 1 Alterations of the haem axis are associated with disease severity in children with malaria. Plasma samples were collected at presentation.
Higher plasma levels of haemin, an oxidized form of haem, and lower levels of haemopexin and haptoglobin were associated with SMA and
CM in Ugandan children compared to children with UM. Kruskal–Wallis Test followed by Dunn’s Multiple Comparison Test, *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001

Excluding the children with the protective sickle cell
trait (HbAS) from the analysis did not alter the associations of the haem axis markers. In summary, these data
are consistent with the hypothesis that severe malarial
syndromes are associated with changes in the haem axis.
Experimental cerebral malaria

BALB/c mice infected with P. berghei ANKA had significantly improved survival compared to the C57BL/6 mice
(40 % survival vs 0 %, p = 0.003) with similar levels of
parasitaemia during the course of infection (Fig. 3a, b).
When the susceptible mice were exhibiting signs of ECM
(day 6 or day 7 post infection), the plasma levels of haemopexin were significantly higher in BALB/c mice compared to the more susceptible C57BL/6 mice [4185 ug/
mL (3557, 4550) vs 3080 ug/mL (1814, 3472), p = 0.005;
Fig. 3d]. Furthermore, mice with targeted disruption of

the hpx gene had significantly decreased survival compared to their wild type littermates (10 vs 38 % survival,
p = 0.022; Fig. 4a). This was associated with significantly
higher levels of plasma haemin at day 7 post infection
in the haemopexin knockout animals compared to the
wild type animals [>8.4 uM (7.3, 8.4) vs 3.6 (3.2, 5.6),
p = 0.005; Fig. 4c]. The haemopexin heterozygous mice
had approximately half the circulating levels of haemopexin than their wild-type counterparts throughout
the course of infection (Fig. 4d) but responded more
similarly to the haemopexin-null mice. There was a
trend towards a difference in survival between the haemopexin heterozygous mice compared to their wild-type
littermates but it did not reach statistical significance (18
vs 38 % survival, p = 0.068; Fig. 4a). There were no differences observed in peripheral parasitaemia (Fig. 4b)
or weight loss between the genotypes. Haemopexin

Elphinstone et al. Malar J (2015) 14:511
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Fig. 2 Plasma levels of haemin and cell-free haemoglobin are associated with disease outcome in severe malaria. Children who died of SM, either
SMA or CM, had higher plasma levels of haemin and cell-free haemoglobin at presentation compared to children who survived SM. Levels of hae‑
mopexin and haptoglobin were lower than those observed in children with UM but were not significantly different between those who survived
SM and those who did not. The dotted lines indicate the median levels observed in children with UM. Mann–Whitney test, *p < 0.05

knockout animals and their wild-type counterparts succumb to ECM during the ECM window (days 6–10);
these mice begin to die roughly 2 days later than the
C57BL/6 mice due to a lower inoculum (105 vs 106 parasitized erythrocytes, respectively). The mice that survived
this period succumbed to anaemia/hyperparasitaemia
and/or had to be euthanized due to weight loss (>20 %).
In response to acute haemolysis, haemopexin-deficient
mice increase their plasma levels of haptoglobin to a
greater degree than their heterozygous or wild-type littermates throughout the course of infection (p = 0.0002;
Fig. 4e). Mice deficient in haemopexin displayed higher
median levels of haptoglobin at baseline prior to infection (89 ug/mL compared to undetectable) compared to
their wild-type counterparts. Following infection, haptoglobin levels in the haemopexin-null mice reached a

peak at day 7 post infection with a median of 1324 ug/mL
while the levels in both the haemopexin wild type and
haemopexin heterozygous mice remained undetectable.
When the mice were moribund, the haptoglobin levels in
the haemopexin-deficient mice had dropped to a median
of 783 ug/mL, while the other genotypes continued to
have undetectable levels of haptoglobin. Together, these
data are consistent with the hypothesis that haemopexin
is playing a mechanistic role during ECM.

Discussion
SM is a complex, multi-organ syndrome that is poorly
understood. This study provides evidence that increased
generation of plasma haem, combined with lower levels of haemopexin that normally binds and clears haem,
are associated with both SMA and CM in Ugandan

Elphinstone et al. Malar J (2015) 14:511
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Fig. 3 Endogenous levels of haemopexin are associated with susceptibility to experimental cerebral malaria. a BALB/c mice are more resistant to
ECM than C57BL/6 mice as demonstrated by improved survival (pooled data from two biological replicates; n = 15–17 per group; log rank test,
**p < 0.01). Both strains of mice had similar levels of b parasitaemia throughout the course of infection (representative data from a single experi‑
ment; n = 7-8/group); c BALB/c mice had higher levels of plasma mouse (m) haemopexin compared to the more susceptible C57BL/6 mice when
moribund (pooled data from two biological replicates; n = 12–13/group). mHpx Mann–Whitney test; **p < 0.01

children. Furthermore, decreased or depleted levels of
haemopexin, and increased plasma haem, are associated
with a worse outcome in a pre-clinical model of CM.
These observations support the hypothesis that haeminduced pathology, exacerbated by decreased levels of
haemopexin, may be a pathway of injury contributing to
disease severity and death in malaria infections.
The observed median plasma levels of haemin in children with CM and SMA were ten-fold or higher than that
observed in UM [12], and equivalent to those reported
in haemolytic disorders such as sickle cell disease [4],
where haem-induced vasculopathy is a frequent cause of
organ dysfunction and mortality [8]. Although there were
no differences in cell-free haemoglobin levels between
groups, given the 11–15-fold higher levels of plasma haemin observed in children with SMA and CM and that
cell-free haemoglobin generates haem, it is likely that
there were also differences in levels of plasma haemoglobin during the course of infection, but the timing of sample collection did not capture these events.
Previously it has been shown that plasma levels of haem
are higher on day 6 post infection in the ECM-susceptible

C57BL/6 mice compared to ECM-resistant BALB/c mice
[13]. Injections of haemin into resistant BALB/c mice
infected with P. berghei ANKA resulted in increased
fatalities compared to controls (100 vs 0 %) [13, 14], suggesting that haem may play an important role in mediating, or enhancing, disease severity. While a role for haem
has previously been implicated in ECM, it had yet to be
confirmed in informative human populations. Recently,
Dalko et al. showed that adults with SM in India had elevated levels of plasma haem compared to those with mild
malaria, which were both higher than levels measured
in endemic controls [15]. These findings were extended
in this study to show an association between increased
haem and disease severity in African children with SM
compared to those with UM.
It is hypothesized that haem is mediating adverse outcomes during malaria infection by inducing endothelial
dysfunction and microvascular injury. Haem is implicated, directly or indirectly, as a key mediator of endothelial dysfunction by a variety of pathways. Plasma haem
is a major source of reactive oxygen species (ROS) and
subsequent pro-oxidant stress on endothelium [8]. Haem

Elphinstone et al. Malar J (2015) 14:511
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Fig. 4 Haemopexin-deficient mice are more susceptible to experimental cerebral malaria. a Both haemopexin knockout (Hpx KO) and haemopexin
heterozygous (Hpx HT) mice have decreased survival during ECM than their wild type (Hpx WT) littermates (pooled data from four biological repli‑
cates; n = 39–44/group; log rank test, *p < 0.05). All three genotypes had similar levels of b parasitaemia (representative data from a single experi‑
ment; n = 7–12/group). The Hpx KO animals had significantly higher levels of c plasma haemin on day 7 post infection, Mann–Whitney, **p < 0.01.
The dotted line indicates upper limit of detection for the assay (8.4 uM). The plasma levels of d haemopexin, and e haptoglobin throughout the
course of infection (n = 4/group); two-way ANOVA, d p = 0.0018, e p = 0.0002. Samples were collected on day 0 and day 7 post infection, then at
cardiac puncture (CP) when mice were moribund

also induces activation of the endothelium by: inducing
Weibel-Palade body exocytosis and the release of their
contents, including the release of von Willebrand factor (vWF), p-selectin [4, 6], and Ang-2, and increasing
expression of endothelial adhesion markers that bind
both inflammatory cells and parasitized erythrocytes
[6]. Haem is also a pro-inflammatory molecule that can
stimulate complement activation [4] and the release
of pro-inflammatory cytokines from monocytes/macrophages [16]. Haem-induced endothelial injury may be
further exacerbated by decreases in bioavailable nitric
oxide. Cell-free haemoglobin in addition to generating
plasma haem, is a potent scavenger of nitric oxide, further amplifying endothelial dysfunction [8, 17]. Many of
these pathways induced by haem are also implicated in
the pathogenesis of SM [3, 17–23]. Further prospective
studies are required to define which of the above pathways are induced by haem in the context of SM.
The toxic effects of cell-free haemoglobin and haem
are normally mitigated by high affinity-binding to haptoglobin and haemopexin, respectively, followed by
transport and degradation. Haem is degraded by haem
oxygenase-1 resulting in the generation of biliverdin and
carbon monoxide which have anti-inflammatory and

endothelial stabilizing effects [8]. Therefore, the excess
generation of haemin observed in children with CM and
SMA appears to be further complicated by a relative deficiency in circulating haemopexin. Previous studies have
primarily focused on levels of haptoglobin [12, 24–26]
or haemopexin [24–26] in UM. However, it was recently
shown that adults with SM in India had decreased levels
of haemopexin compared to those with mild malaria [15].
Similarly, in this study it was observed that children with
SMA had significantly lower levels of both haemopexin
and haptoglobin, in agreement with a previous report
[25]. This study extends these previous findings and
reports that African children with CM also have lower
levels of both haemopexin and haptoglobin, suggesting
a common pathway of endothelial injury in both CM
and SMA, and in both adults and children with severe
disease. Despite the markedly low levels of these protective proteins in children with CM or SMA, there were
no observed differences in either haemopexin or haptoglobin levels between children who survived or died
of the infection. These data suggest that these proteins
are already depleted during severe infection. Whether
these relative deficiencies are due to consumption or due
to a decreased capacity to synthesize these proteins in
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response to haemolysis is unknown. Nonetheless, these
low levels would be expected to further compromise
clearance and degradation of haem and haemoglobin,
and contribute to worse clinical outcomes, as was illustrated by the observed higher plasma levels of haemin
and cell-free haemoglobin in children who subsequently
died of malaria.
Due to the associations observed in children with CM
or SMA, a potential mechanistic role for haemopexin
was investigated using a pre-clinical model of ECM. As
with all animal models, there are inherent limitations.
However, there is evidence that this model shares several features, but not all, with human malaria [27–32].
Pre-clinical models enable investigation of mechanistic
questions that are difficult to safely or ethically address
in human populations and can provide direct genetic evidence that the haem axis is causally involved in severe
and fatal infection.
Similar to this patient population, mice that were more
susceptible to ECM had significantly lower haemopexin
levels compared to more resistant mice, despite comparable parasite burdens. Furthermore, mice with targeted
deletion of the hpx gene, and no measurable circulating haemopexin, were more susceptible to ECM than
their wild-type littermates suggesting that haemopexin is
playing a mechanistic role during malaria infection. The
increased susceptibility in the Hpx KO animals was associated with increased levels of plasma haemin prior to the
onset of ECM, further implicating a role for plasma haem.
A dose response to ECM was predicted due to the gene
dosing effect observed in these mice; however, both the
haemopexin-null and heterozygous mice responded similarly to ECM. The haemopexin-null mice appear to compensate for their lack of haemopexin by increasing the
production of haptoglobin. The haemopexin-null mice
have higher baseline levels of haptoglobin compared to
both the wild type and heterozygous mice. When infected
with P. berghei ANKA, haemopexin-deficient mice further upregulate circulating haptoglobin to at least 1300
times the levels seen in either the wild type or heterozygous mice. This compensation in a protein upstream of
haemopexin in the haemolytic pathway is hypothesized
to mitigate the severity of the observed phenotype. The
haemopexin heterozygous mice may more accurately
reflect the impact of haemopexin deficiency in ECM due
to their inability to compensate with increased levels of
haptoglobin to the levels observed in haemopexin-null
mice. It would be of interest to further explore the phenotype of a double haemopexin, haptoglobin knockout
mouse in the ECM model.
Despite the marked increase in haptoglobin, haemopexin-null mice are still more susceptible than their
wild-type counterparts. This is likely attributable to
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malaria-induced generation of plasma haemoglobin and
haem that overwhelms both haptoglobin and/or haemopexin pathways, as demonstrated by significantly
higher levels of plasma haem prior to the onset of ECM
in the KO animals. Alternatively, haemopexin may provide additional protection independent of its ability to
clear haem from the circulation. Haemopexin has been
shown to exert haem-independent, anti-inflammatory
effects by decreasing the release of pro-inflammatory
cytokines from lipopolysaccharide (LPS) stimulated macrophages [33], and decreased differentiation of TH17
cells in a model of experimental autoimmune encephalitis [34].
Collectively, the above observations suggest that
malaria-induced haem, and corresponding haemopexin
deficiency may represent a component of disease pathogenesis in which haem amplifies complement activation,
pro-coagulant activity and endothelial injury, culminating
in microangiopathy, multi-organ dysfunction and adverse
clinical outcomes. The recent observation that both cases
of CM and SMA are associated with parasitized erythrocytes that bind to endothelial protein C receptor (EPCR)
lends further support to this hypothesis [35]. Binding to
EPCR may disrupt the anti-inflammatory and endothelial barrier effects of activated protein C (APC), resulting
in enhanced pro-coagulant activity, complement activation and endothelial injury. Of note, APC mediates its
endothelial cytoprotective and barrier protective activities via the Ang-Tie2 pathway [36], which is dysregulated in SM [37]. Moreover, since parasitized erythrocyte
sequestration focuses parasite burdens and erythrocyte
haemolysis directly onto the microvasculature of vital
organs, this would be expected to result in higher local
haem concentrations in the cerebral microvascular bed,
than those observed in the peripheral circulation.
Similar to atypical haemolytic uremic syndrome
(aHUS) associated with infection, where haem-induced
complement activation is a proposed common pathway
of microvascular injury and organ failure, severe disease
does not occur in all infected individuals, but rather only
in those with genetic or acquired defects in complement
regulation [4]. This suggests that similar or related susceptibility determinants, including defects in haemopexin
expression or haem metabolism, may contribute to the
onset and outcome of severe malarial syndromes.

Conclusions
These data support the hypothesis that elevated plasma
haem contributes to the pathobiology of severe and
fatal malaria. Future studies will need to confirm these
findings and investigate other potential interactions
(e.g., Ang-Tie2 axis) contributing to haem axis dysfunction in children with severe malarial syndromes. The
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identification of plasma haem as a potential mediator
of disease pathogenesis suggests potential therapeutic
interventions, including the administration of exogenous
haemopexin which has been shown to confer protection
to haem-induced endothelial injury in models of chronic
haemolysis [8], and in models of sepsis [7].

Additional file
Additional file 1: Figure S1. Alterations in the haem axis in children
with (A) severe malarial anaemia or (B) cerebral malaria based on disease
outcome. There was a trend towards higher plasma levels of haemin
and cell-free haemoglobin at presentation in children who died of the
infection compared to those who survived; however, these associa‑
tions are likely underpowered to reach statistical significance (haemin:
SMA p = 0.14, CM p = 0.14; haemoglobin: SMA p = 0.06, CM p = 0.25).
There was no observable difference between levels of haemopexin and
haptoglobin and disease outcome in children with either SMA or CM. The
dotted lines indicate the median levels observed in children with UM.
Mann–Whitney test.
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